Study reveals tricky platelet swings in blood disorder drug response
NCT ID NCT05876221
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessary extra treatment. The goal was to identify these patterns and help guide safer, more accurate care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Caplacizumab (Cablivi)
- What this could lead to
- If successful, this could help doctors better interpret platelet counts during caplacizumab treatment, reducing unnecessary therapy adjustments and side effects.
- What could go wrong
- This is a retrospective analysis, not a controlled trial, so it cannot prove cause and effect. The findings may not apply to all patients or change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Cologne
Cologne, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.